Ipilimumab: tested with established drugs
41 studies: they are given beside it. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.RecruitingNCT07134842Phase 1Report a problem
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingNCT05112601Phase 2Report a problem
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedNCT04611126Phase 1/2Results postedReport a problem
- A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results postedReport a problem
- Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainCompletedNCT03873818Phase 2Results postedReport a problem
- Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)CompletedNCT03302234Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCompletedNCT03068455Phase 3Results postedReport a problem
- Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02823574Phase 2Results postedReport a problem
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersActive, not recruitingNCT02785952Phase 3Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results postedReport a problem
- Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinCompletedNCT02279732Phase 3Results postedReport a problem
- Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01820754Phase 2Results postedReport a problem
- Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerCompletedNCT01804465Phase 2Results postedReport a problem
- Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01708941Phase 2Results postedReport a problem
- Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneCompletedNCT01450761Phase 3Results postedReport a problem
- Ipilimumab + Androgen Depravation Therapy in Prostate CancerTerminatedNCT01377389Phase 2Results postedReport a problem
- Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinCompletedNCT01285609Phase 3Results postedReport a problem
- Neoadjuvant Ipilimumab in Prostate CancerCompletedNCT01194271Phase 2Results postedReport a problem
- Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung CancerCompletedNCT01165216Phase 1Results postedReport a problem
- Ipilimumab + Temozolomide in Metastatic MelanomaCompletedNCT01119508Phase 2Results postedReport a problem
- Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic CancerCompletedNCT00836407Phase 1Results postedReport a problem
- Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain MetastasesCompletedNCT00623766Phase 2Results postedReport a problem
- Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)CompletedNCT00527735Phase 2Results postedReport a problem
- Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaCompletedNCT00324155Phase 3Results postedReport a problem
- Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate CancerCompletedNCT00170157Phase 2Results postedReport a problem
- Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic TherapyCompletedNCT05665348Phase 2/3Report a problem
- Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCActive, not recruitingNCT05401786Phase 2Report a problem
- Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2Report a problem
- A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCompletedNCT04132817Phase 1Report a problem
- A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActive, not recruitingNCT03873402Phase 3Report a problem
- Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic MelanomaCompletedNCT01743157Phase 1/2Report a problem
- Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical CancerCompletedNCT01711515Phase 1Report a problem
- Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for MelanomaCompletedNCT01608594Phase 1Report a problem
- Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate CancerTerminatedNCT01510288Phase 1Report a problem
- Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT00871481Phase 1/2Report a problem
- Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289640Phase 2Report a problem
- A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289627Phase 2Report a problem
- A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideCompletedNCT00135408Phase 2Report a problem
- Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1Report a problem
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1Report a problem
- Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate CancerCompletedNCT00050596Phase 2Report a problem